Clinica Oncologica, Ospedali Riuniti Umberto 1

Ancona 60126

0 studies enrolling now · 2 studies all time

What they study most

Cholangiocarcinoma, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling